After the C.R announcement February 2018 I got the impression that the focus of 2b appeared to be on completing FSGS studies and Diabetic Nephropathy trials were perhaps requiring more time/partnering/funds.
Feb 21st 2018 announcemenout extract
Dimerix is now fully funded to further the Company’s development plans and to take our lead compound, DMX-200 into a Phase 2 trial this quarter for the treatment of the rare kidney disease, FSGS. The funding will enable us to complete the steps required to develop commercial scale batches of DMX-200, and complete the remaining non-clinical studies to take DMX-200 to Phase 3 ready for FSGS.
Importantly, we are now in a strong position to continue our partnering discussions and exploit the full commercial potential for DMX-200 in diabetic nephropathy, and other pipeline opportunities."
The impression I'm getting from yesterdays information I read in the NDF release is that diabetic nephropathy has moved up and is included in the focus of 2b with a small FSGS trial being run simultaneously. Interesting given share register clean up.
NDF Release 13/02/18
Dimerix’s lead DMX-200 candidate, an adjunct therapy of two safe and approved drugs, irbesartan and propagermanium, completed, in mid-2017, a Phase 2a study in patients with proteinuria, which is symptomatic of a range of kidney problems.
Dimerix is now preparing a Phase 2b for DMX-200, expected to initiate in the second half of calendar 2018, that will recruit patients with Diabetic Nephropathy, where the Phase 2a data was particularly encouraging1 . Alongside this study, Dimerix intends to conduct a small, 10-patient proof-of-concept study in FSGS, preparatory to taking DMX-200 into a pivotal study in FSGS from late 2019 or early 2020 after the Phase 2b.
Add to My Watchlist
What is My Watchlist?
